Welcome to the Hepatology department of Royal Surrey NHS Foundation Trust. The team comprises four consultant hepatologists looking after patients with liver disease. Our consultants are supported by five hepatology/viral hepatitis specialist nurses, an award-winning alcohol liaison team, and an outreach Hepatitis C team who are the winners of the Nursing Times Community Nursing award, and the South East regional winner in the Health Equalities Award Category of the NHS Parliamentary Awards.
We run clinics for viral hepatitis, autoimmune liver disease, liver cirrhosis, vascular liver disease and alcohol-related liver disease and manage all aspects of metabolic liver disease including non-alcohol fatty liver disease (NAFLD), hereditary haemochromatosis and Wilson's disease.
The team provide day care services for paracentesis and a nurse lead venesection service treating over 100 haemochromatosis patients. Fibro-scanning is also provided as an integral part of the liver service.
Our consultants have all trained in liver transplant centres and look after patients who have received liver transplants or who have transplant-related complications. Our consultants are also core members of the hepatopancreatobiliary (HPB) multidisciplinary team and have extensive experience in the management cancer originating in the liver, the biliary tree, the pancreas and the gallbladder. They are also responsible for providing therapeutic endoscopy service in and out of hours.
We pride ourselves in being the only district general hospital in the country commissioned to deliver therapy for patients with hepatitis C (Operational Delivery Network -ODN). We are also the regional centre providing therapy for the rare liver disorder primary biliary cholangitis (PBC). Moreover, we are a recognised global centre of excellence for the management Wilson disease as recognised by the Wilson Disease association (WDA).
The team is comprised of four consultant hepatologists looking after patients with liver disease. Our consultants are supported by five hepatology / viral hepatitis specialist nurses, an award-winning alcohol liaison team and an outreach Hepatitis C team who are the winners of the Nursing Times Community Nursing award and are the South East regional winner in the Health Equalities Award Category of the NHS Parliamentary Awards.
Prof. Aftab Ala
Dr Michelle Gallagher
Dr Sanju Mathew
Dr Marinos Pericleous
Dr Dushen Murguiah
Secretary to: Prof Aftab Ala and Dr Marinos Pericleous
01483 571122 Ext. 6990
Secretary to: Dr Michelle Gallagher
01483 571122 Ext. 6519
Secretary to: Dr Sanju Mathew, and Dr Dushen Murguiah
01483 571122 Ext. 4933 / 5239
We have extensive experience in clinical and translational research and, over the years, have built strong regional, national and international collaborations. The Royal Surrey is the regional South East England hub for the local clinical research network (LCRN) for National Institute for Health and Research (NIHR). We have expertise in translational research related to chronic viral hepatitis, rare genetic liver diseases such as Wilson diseases and PBC, liver cancer and more recently COVID-19. In 2018, we received an NIHR National Award of recognition for the greatest increase in clinical trial studies in any UK Hepatology clinical research network.
You might find the following websites useful for information and advice. Please note that Royal Surrey NHS Foundation Trust is not responsible for the content or updating of these sites.
Alcohol Change UK
A charity promoting alcohol change, working towards improved knowledge, better policies and regulation, shifted cultural norms, improved drinking behaviours, and more and better support and treatment.
British Liver Trust
The UK's leading liver health charity.
Love Your Liver
A British Liver Trust national awareness campaign devoted to liver health awareness and giving people the key steps needed to keep their liver healthy.
NHS: BMI healthy weight calculator
Use the calculator on the NHS website to check your body mass index and find out if you are a healthy weight.
The Wellness Toolbox - Cirrhosis
Providing nutrition and exercise resources to help you stay healthy when living with cirrhosis.
Helping people live with iron overload.
UK-AIH is a research collaboration with a shared interest in understanding and treating the autoimmune liver disease autoimmune hepatitis.
The Hepatitis B Positive Trust UK
Aiming to end the silence around hepatitis B infections and draw together people with hepatitis B to give them a collective voice and the ability to support each other.
The Hepatitis C Trust
Raising public awareness of the virus, ending discrimination about people with hepatitis C, and creating an active community of patients.
Non-alcoholic fatty liver disease
NHS: Non-alcoholic fatty liver disease
Find information about non-alcoholic fatty liver disease on the NHS website.
Pancreatic Cancer UK
Providing expert support and information, funding research and campaigning for change.
Primary Biliary Cholangitis (PBC)
A charity offering support to PBC sufferers, their family and friends.
Helping anyone affected by PSC and driving research towards a cure.
Wilson's Disease Support Group UK
Support, education and outreach for people living with Wilson's disease, their family and friends.
British Association for the Study of the Liver
Dedicated to advancing knowledge and understanding of the biology and pathology of the liver for the optimal care of patients.
Improving Quality in Liver Services
A Royal College of Physicians programme, aiming to improve the quality of medical liver services throughout the UK.
Grants to the department (2015 - current)
2020 Developing and Delivering targeted SARS-CoV-2(COVID-19) health interventions to Black, Asian and Minority Ethnic (BAME) communities living in the UK- The Cobham Study (AA Chief Investigator £371,734)
2019 Wilson Disease Association to develop and deliver UK-USA Wilson Disease Registry Programme (AA Chief Investigator $278,690, 4 years)
2018 NIHR Doctoral fellowship “Using telemedicine to improve access and quality of secondary care for people in prison, and cost effectiveness of health care provision” AA Clinical Supervisor (£426,800) 4 years
2018 Wilsons Disease Association to support USA- Europe Wilson disease Natural History Registry programme. AA Chief Investigator $251,000 3 year
2018 Wilson Disease Association (WDA USA) to support Clinical Research fellow programme to work at Royal Surrey County Hospital (AA $50,000) 1 year
2017 Wilson Disease Association (WDA USA) to support Clinical Research fellow programme to work at Yale University – “Developing the Wilson registry programme” (AA $78,000) 1 year
2017 Academic Programme Activity Award Royal Surrey County Hospital to support clinical trials programme (£11,500) 1 year
2016 Europe and Canada Practise to Policy Health Awards programme: 25,000 Euros- Characterising linkage in the PBC patient from primary to secondary care in South England. AA/MP (25,000 Euros)
2015 National Institute for Health and Research (NIHR) RfPB PB-PG-1013-32094 – An Innovative Educational Intervention to Improve Uptake of Hepatitis B And C Testing In South East Asians: Intervention Development and A Feasibility Study for a Randomised Control Trial. Chief Investigator: AA. (£329,421) 2.5 years
2015 Improving the detection and uptake of LAL(lysosomal acid lipase) deficiency and uptake in South East England at risk individuals. Alexion Pharmaceuticals. Chief Investigator: AA (£47,000). 1 year
2015 Real world PBC (Primary Biliary Cirrhosis) patient pathways in South East England. Chief Investigator Aftab Ala . Intercept Pharmaceuticals. (AA £43,000). 1 year
2015 NIHR Clinical Research Network(CRN) Kent, Surrey and Sussex Clinical Research Strategic Funding for Hepatology Trial Management. Chief Investigator: AA (£6,000) 1 year
|Short Title||Full Title|
|A Phase 3 Double Blind, Randomized Placebo Study of MGL‐3196||A Phase 3, Multinational, Double-Blind, Randomized, Placebo-Controlled Study of MGL-3196 (resmetirom) in Patients With Non-Alcoholic Steatohepatitis (NASH) and Fibrosis to Resolve NASH and Reduce Progression to Cirrhosis and/or Hepatic Decompensation|
|A study to evaluate JNJ-64300535 DNA vaccine in chronic Hepatitis B||A first-in-human, double-blind, randomized, placebo-controlled, Phase 1 study to evaluate the safety, tolerability, reactogenicity, and immunogenicity of JNJ-64300535, a DNA vaccine, administered by electroporation-mediated intramuscular injection, in participants with chronic hepatitis B who are on stable nucleos(t)ide therapy and virologically suppressed.|
|Albumin To prevenT Infection in chronic liveR failurE (ATTIRE)||Albumin To prevenT Infection in chronic liveR failurE (ATTIRE)|
|AURORA||A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Cenicriviroc in Adult Subjects with Nonalcoholic Steatohepatitis and Liver Fibrosis|
|Beta-blockers or placebo for primary prophylaxis (BOPPP) Trial||Beta Blockers or placebo for primary prophylaxis of oesophageal varices (BOPPP Trial). A blinded, multi-centre, clinical effectiveness and cost-effectiveness randomised controlled trial|
|CHELATE STUDY GMPO-131-002||CHELATE STUDY: Trientine tetrahydrochloride (TETA 4HCl) for the treatment of Wilson’s disease|
|COBHAM study||Developing and Delivering targeted SARS-CoV-2(COVID-19) health interventions to Black, Asian and Minority Ethnic (BAME) communities living in the UK|
|HEPA - 5032 The REGENERATE Study||A Phase 3, Double-Blind, Randomized, Long-Term, Placebo-Controlled, Multicenter Study Evaluating the Safety and Efficacy of Obeticholic Acid in Subjects with Nonalcoholic Steatohepatitis|
|HEPA 4066 (Wilson Disease)||A Phase 2, Multi-centre, Open-label, Study to Evaluate the Efficacy and Safety of WTX101 Administered for 24 Weeks in Newly Diagnosed Wilson Disease Patients Aged 18 and Older with an Extension Phase of 12 Months|
|Methotrexate induced liver fibrosis||Evaluation of the role of AST:ALT ratio, ELF markers and fibroscan in the detection of methotrexate induced hepatotoxicity|
|NAFLD BioResource||The NAFLD BioResource, part of the NIHR BioResource – A Research Study to Characterise Novel Clinical and Genetic Phenotypes, and Understand the Natural History of Non-Alcoholic Fatty Liver Disease (NAFLD)|
|NASH Genotype||Case-control Study Evaluating the Genetic Factors Associated with the Development of Non-Alcoholic Steatohepatitis|
|Natural history and pathogenesis of systemic IgG4 disease||Natural history and pathogenesis of systemic IgG4 disease|
|Norursodeoxycholic acid vs. Placebo in PSC||Double-blind, randomized, placebo-controlled, phase III study comparing norursodeoxycholic acid capsules with placebo in the treatment of primary sclerosing cholangitis|
Michael Schilsky - Yale University, USA Wilsons disease
Prof Karl Heinz Weiss, Heidelberg University, Germany - Liver cancer and Wilsons disease
Professor Seema Alam, ILBS, New Delhi, India Wilsons disease
Professor Peter Ott, Copenhagen, Denmark Wilsons disease
Sir Professor Alimuddin Zumla - UCL, London, COVID-19
Professor Anil Dhawan, Kings College Hospital, London
Professor Andrew Hayward- UCL, COVID-19
Professor Jane Hendy- Brunel University, London
Dr Usman Darr, Chatham House, London
Dr Chris Harrington, Trace Elements Laboratory, Royal Surrey